Gilead Sciences CMO: Remdesivir Efficacy Awaits Clinical Validation, Company Ramping Up 24/7 Production

Original Title: Gilead Sciences’ Chief Medical Officer: Remdesivir’s Efficacy Still Awaits Clinical Validation; Production Ramping Up 24/7 to Maximum Capacity Source:Xinhua Net

E Company News: In an interview, Dr. Merdad Parsey, Chief Medical Officer of Gilead Sciences, stated that the efficacy of remdesivir still awaits clinical validation. Researchers expect to obtain partial data in approximately one month, and the drug is currently being produced around the clock to the fullest extent possible.